CN105708794A - Medicine for treating periodontitis - Google Patents

Medicine for treating periodontitis Download PDF

Info

Publication number
CN105708794A
CN105708794A CN201610156078.1A CN201610156078A CN105708794A CN 105708794 A CN105708794 A CN 105708794A CN 201610156078 A CN201610156078 A CN 201610156078A CN 105708794 A CN105708794 A CN 105708794A
Authority
CN
China
Prior art keywords
salanesol
periodontitis
medicine
treating periodontitis
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610156078.1A
Other languages
Chinese (zh)
Inventor
汪显国
王慧
李庆华
唐丽
唐军
和红兵
任晓斌
杨晶津
陈兴
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hongyun Honghe Tobacco Group Co Ltd
Original Assignee
Hongyun Honghe Tobacco Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hongyun Honghe Tobacco Group Co Ltd filed Critical Hongyun Honghe Tobacco Group Co Ltd
Priority to CN201610156078.1A priority Critical patent/CN105708794A/en
Publication of CN105708794A publication Critical patent/CN105708794A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
    • C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
    • C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

The invention discloses medicine for treating periodontitis. A preparation method of the medicine comprises the following steps: 1, selecting plants containing solanesol as raw materials, and extracting and purifying solanesol, wherein the purity is not lower than 90%; 2, diluting the purified solanesol with soybean oil, so that a medicinal solution with the concentration being 3.0-0.6 mg/100g is obtained. The medicine for treating periodontitis has the practical advantages that the principle is simple, operation is convenient to conduct, positions and depths of temperature detecting points can be adjusted conveniently, a temperature sensor is easy to mount and dismount.

Description

A kind of medicine treating periodontitis
Technical field
The invention belongs to medicine and biological field, be specifically related to a kind of medicine treating periodontitis.
Background technology
Salanesol is a kind of undersaturated isopolyprenols, belongs to four sesquiterpenoids, and molecular formula is C45H14O, and nonpolarity or low pole is water insoluble；It is slightly soluble in methanol, ethanol；It is dissolved in acetone, chloroform.It is widely present in plant of Solanaceae, Folium Mori, Rhizoma Solani tuber osi, especially with the content in tobacco leaf the highest (0.5%～1.2%).Salanesol itself contains multiple unconjugated double bonds, therefore has the performance absorbing free radical strongly.Horse Magnolia denudata etc. adopt the oxidation resistance of antioxidation in vitro system and internal antioxidation scale-model investigation Salanesol, and result display Salanesol is removed mouse thymus cells system and produced O2-Ability, when 8mmol/L, clearance rate reaches 82.4%；Illustrate that Salanesol has good lipoid peroxidization resistant, the research such as Bai Qi display that Salanesol can effective Ultraviolet radiation absorbing, effectively removing lipid free radical and block lipid peroxidation, and effectively suppress tryrosinase.
Periodontitis is a kind of by the microbial chronic infectious disease of certain detail, is characterized in that the Progressive symmetric erythrokeratodermia of Periodontal Supporting Tissue destroys, can cause gingiva, periodontal membrane, alveolar bone and the infringement of cemental irreversibility.Treating the mode of periodontitis at present mainly from suppressing bacterial plaque microorganism and regulating the aspect of immunity of organisms, the medicine adopted includes antibiotic and the immunomodulating class medicines such as LIUWEI DIHUANG WAN, bushen guchi pills such as amoxicillin, tetracycline, minocycline；Along with research in recent years, excess activity oxygen the dependency that the oxidative stress produced occurs with periodontitis and develops increasingly receives the concern of people.Research shows, under inflammatory conditions, body defenses cell can produce excessive ROS, then forms oxidative stress when ROS accumulates too much in vivo, and by aoxidizing the biomolecule of various cells and tissue, thus adding the hyperphlogosis infringement to tissue.
Summary of the invention
The technical problem to be solved in the present invention is to provide the mechanism of a kind of formation based on periodontitis, in conjunction with the oxidation resistance of Salanesol, is reached the medicine of the treatment periodontitis of the purpose for the treatment of periodontitis by antioxidative effect.
For solving the problems referred to above, the present invention adopts the following technical scheme that
A kind of medicine treating periodontitis, comprises the following steps:
1) choosing the plant containing Salanesol is raw material, and extraction purification Salanesol, purity is not less than 90%；
2) Salanesol purified dilutes with soybean oil, forms the drug solution of concentration 3.0mg/100g～6.0mg/100g；
Further, in step 1) in, the method for described extraction purification Salanesol is: chooses waste tobacco leaf powder and adds methanol-acetone mixed solution, reflux, extract, concentrated extracting solution, obtains extractum；Extractum is dissolved in methanol, adds petroleum extn 3 times, concentrating under reduced pressure, obtain petroleum ether extract；Separation, purification, saponification, add petroleum ether, enrichment, obtain Salanesol.
Further, in step 2) in, the drug solution prepared is by 1ml/100g to Periodontitis Model mouse gavage, and successive administration is not less than surrounding.
The invention have the benefit that the Salanesol adopting extracted form natural plant is as medicine, has no side effect；After treating with Salanesol, effect is obvious, and swelling and aching of gum substantially alleviates, and visits and examines hemorrhage minimizing, corresponding inflammatory factor, as IL-1 β, TNF-α etc. suppress substantially.
Accompanying drawing explanation
Fig. 1 is Histological section's comparison diagram before and after the administration of periodontitis mouse model；
Wherein, CEJ is that enamelo-cemental junction (cemento-enameljunction, CEJ), ab (alvcolarbone) represent tooth grain ridge, ct (connectivetissue) represents connective tissue, and d (dentin) represents dentin.
Detailed description of the invention
For making the architectural feature to the present invention and effect of reaching have a better understanding and awareness, coordinate detailed description in order to preferred embodiment and accompanying drawing, illustrate as follows:
1. Salanesol purifies
Choose waste tobacco leaf powder and add methanol-acetone mixed solution, reflux, extract, concentrated extracting solution, obtain extractum.Extractum is dissolved in methanol, adds petroleum extn 3 times, concentrating under reduced pressure, obtain petroleum ether extract.Separation, purification, saponification, add petroleum ether (normal hexane), enrichment, obtain purity and reach the Salanesol of 95%.
2. build mice Periodontitis Model
Choose the cleaning grade male SD rat 120 that Bill's animal cultivation field, letter city, Jianyang City of Sichuan Province provides, 6 weeks, body weight 180-220g；Being randomly divided into five groups, normal group 30, experiment component are matched group (not being administered), dosage I group and dosage II group, often organize each 30；After experimental group rat adaptability feeds l week, 10% chloral hydrate presses 0.3ml/100g intraperitoneal injection of anesthesia, and rat dorsal position is fixed, and uses 4/0# medical wire, and in rats with bilateral maxillary second molar ring neck portion's ligation, tie a knot in tongue side, and makes silk thread be positioned at gingival sulcus as far as possible.With method ligation offside maxillary second molar, and start to feed l00g/L sucrose and soft diet (conventional Mus material sucrose blister system) from experimental day, experimental group using maxillary second molar enamelo-cemental junction to the distance of alveolar ridge crest as the successful evaluation criterion of model construction.
Embodiment:
1) experimental program
The Salanesol purified with soybean oil dilution, forms the drug solution of concentration respectively 3.0mg/100g and 6.0mg/100g；Every morning 9 gives Salanesol gavage respectively, dilutes medicine with soybean oil.Matched group is according to body weight gavage soybean oil, gavage volume 1ml/100g.
2) sample collection
After gavage 2,4,6 Wednesday time point often group randomly draw the blood sampling of 7 rat aortas, detect for inflammatory factor.After blood sampling, being rapidly separated upper jaw bone, be divided into two, right maxillary bone is soaked in 4% paraformaldehyde fixative, for histology.Left side upper jaw bone is placed in 75% ethanol, is used for measuring Alveolar Bone Loss (alveolarboneloss, ABL).
3) implementation result
1. periodontal situation: randomly draw normal rat and modeling rat detects periodontal tissue's situation, normal rats bilateral maxillary second molar, without soft dirt and tartar, gingiva pinkiness, is belittled tough and tensile and is close to facing, and spy is examined not hemorrhage, without attachment loss.The soft dirt accumulation that modeling group rat neck portion is more, gingiva color is scarlet, edge circle is blunt, red and swollen stripping, and gingiva touches hemorrhage, and alveolar ridge crest is fuzzy is worm-eaten shape, and being caved in by flat change of width in ridge top, phatnoma bone height reduces, and second molar may occur in which that I-II 0 is loosening.After drug treating, treatment group is with the increase for the treatment of time, swelling and aching of gum substantially alleviates, hemorrhage minimizing is examined in spy, it is not all the same that three time points respectively organize Alveolar Bone Loss, compared with model group, alveolar bone all substantially has improvement (see table 1), its Alveolar Bone Loss value periodontitis group > treatment group > normal group.
Table 1, different time points respectively organize rat alveolar bone lose situation (mm)
Compared with normal group,▲P < 0.05；Compared with periodontitis group,●P<0.05。
2. histology: bolt line 2 weeks, 4 weeks and 6 weeks, each group rat periodontium is observed, and sees accompanying drawing 1；After bolt line 2 weeks, 4 weeks and 6 weeks, each group all can find periodontal tissue's destruction in various degree, the especially a large amount of inflammatory cell infiltration of periodontitis group, frontal resorption, and periodontal membrane fiber ruptures.Administration group, compared with periodontitis group, makes moderate progress, and especially dosage II group is at the 4th week substantially.
3. inflammatory Cytokines Expression situation in blood plasma: after being administered 2 weeks, 4 weeks, 6 weeks, administration group IL-1 β, TNF-α express lower will (see table 2, table 3), compare with periodontitis group, have significant difference (P < 0.05).There was no significant difference between two dosage groups of same time point Salanesol, P > 0.05.
Table 2, different time points respectively organize IL-1 β concentration in rat plasma change (pg/ml)
Compared with normal group,▲P < 0.05；Compared with periodontitis group,●P<0.0。
Table 3, different time points respectively organize TNF-α concentration in rat plasma change (pg/ml)
Compared with normal group,▲P < 0.05；Compared with periodontitis group,●P<0.05。
The invention have the benefit that the Salanesol adopting extracted form natural plant is as medicine, has no side effect；After treating with Salanesol, effect is obvious, and swelling and aching of gum substantially alleviates, and visits and examines hemorrhage minimizing, corresponding inflammatory factor, as IL-1 β, TNF-α etc. suppress substantially.
The above, be only the specific embodiment of the present invention, but be not limitation of the present invention, and those skilled in the art's basic thought according to the present invention, it is possible to amendment and improvement, but as long as without departing from the basic thought of the present invention, all within the scope of the present invention.

Claims (3)

1. the medicine treating periodontitis, it is characterised in that comprise the following steps:
1) choosing the plant containing Salanesol is raw material, and extraction purification Salanesol, purity is not less than 90%；
2) Salanesol purified dilutes with soybean oil, forms the drug solution of concentration 3.0mg/100g～6.0mg/100g.
2. the medicine treating periodontitis as claimed in claim 1, it is characterised in that: in step 1) in, the method for described extraction purification Salanesol is: chooses waste tobacco leaf powder and adds methanol-acetone mixed solution, reflux, extract, concentrated extracting solution, obtains extractum；Extractum is dissolved in methanol, adds petroleum extn 3 times, concentrating under reduced pressure, obtain petroleum ether extract；Separation, purification, saponification, add petroleum ether, enrichment, obtain Salanesol.
3. the medicine treating periodontitis as claimed in claim 1 or 2, it is characterised in that: in step 2) in, the drug solution prepared is by 1ml/100g to Periodontitis Model mouse gavage, and successive administration is not less than surrounding.
CN201610156078.1A 2016-03-18 2016-03-18 Medicine for treating periodontitis Pending CN105708794A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610156078.1A CN105708794A (en) 2016-03-18 2016-03-18 Medicine for treating periodontitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610156078.1A CN105708794A (en) 2016-03-18 2016-03-18 Medicine for treating periodontitis

Publications (1)

Publication Number Publication Date
CN105708794A true CN105708794A (en) 2016-06-29

Family

ID=56157908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610156078.1A Pending CN105708794A (en) 2016-03-18 2016-03-18 Medicine for treating periodontitis

Country Status (1)

Country Link
CN (1) CN105708794A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113841658A (en) * 2021-10-13 2021-12-28 昆明医科大学 Rapid building method of periodontitis model and treatment medicine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1395939A (en) * 2002-08-11 2003-02-12 黄景俊 Compound of solanesol and its preparing process
CN101050212A (en) * 2007-05-18 2007-10-10 中南大学 Method for extracting high pure natural nicotine and solanesol at same time from waste and low-grade tobacco

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1395939A (en) * 2002-08-11 2003-02-12 黄景俊 Compound of solanesol and its preparing process
CN101050212A (en) * 2007-05-18 2007-10-10 中南大学 Method for extracting high pure natural nicotine and solanesol at same time from waste and low-grade tobacco

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
夏薇等: "废次烟叶浸膏中茄尼醇的提取", 《中国医药工业杂志》 *
王艳等: "烟叶中制备高纯度茄尼醇的新工艺", 《中成药》 *
陈广垠: "《高血压饮食对症调养：专家教你怎样吃降低高血压》", 31 October 2014 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113841658A (en) * 2021-10-13 2021-12-28 昆明医科大学 Rapid building method of periodontitis model and treatment medicine

Similar Documents

Publication Publication Date Title
CN100420432C (en) Gargle and its preparing process
CN103191039B (en) Mouthwash as well as preparation method and application thereof
CN101628085A (en) Chinese medicinal preparation for treating gingivitis and parodontitis and preparation method thereof
CN113005055A (en) Lactobacillus plantarum for preventing and/or treating periodontitis, culture thereof, and preparation and application thereof
CN103989599A (en) Chinese herbal medicine toothpaste capable of diminishing inflammation and stopping bleeding
CN107625790A (en) Nutgall prevents and treats periodontal disease and the production method of IBD active component and application thereof
CN105726792A (en) Traditional Chinese medicine composition with effects of resisting periodontitis and protecting periodontium and preparation method and application thereof
CN105708794A (en) Medicine for treating periodontitis
CN101085045B (en) Traditional Chinese medicine preparation for treating stomatitis
CN103550274B (en) A kind of medicine preparation for oral cavity
CN1234342C (en) Chinese medicinal tooth-paste
CN102670891B (en) Medicament for treating gingivitis
CN1321657C (en) Buccal tablets for curing acute or chronic pharyngitis and buccal inflammation and the preparation technology thereof
CN102309663B (en) Medicament for controlling dental caries
CN102580035B (en) Medicament for treating periodontitis
CN1323701C (en) Chinese medicinal composition for treating rhinitis and pharyngitis
CN104800117A (en) Traditional Chinese medicine toothpaste for resisting diabetic periodontitis and preparation method of toothpaste
CN1762425A (en) Efervescence tablet with kudzuvine root, scutellarta root, Chinese goldthread and its preparation method
CN103690752B (en) A kind of medicament for the treatment of orthodontic gingivitis
CN103432201A (en) Honeysuckle and baical skullcap root pharmaceutical preparation containing polyethylene glycol 12-hydroxy stearate and preparation method thereof
CN1067896C (en) Externally used medicine for fishes
CN1267116C (en) Medicine for treating gingivitis and periodontitis and preparation method thereof
CN103110552A (en) Preparation method of salix caprea toothpaste
CN117562962B (en) Use of periplaneta americana or extract thereof and veterinary Chinese medicine composition for treating cat stomatitis
CN114146125B (en) Traditional Chinese medicine composition for inhibiting helicobacter pylori infection in oral cavity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160629

WD01 Invention patent application deemed withdrawn after publication